Scientifc Comments

Hypoxia adaption in life——An analysis of Nobel Prize in Physiology or Medicine in 2019

  • ZHAO Li ,
  • LI Jie
Expand
  • Department of Neurobiology, Capital Medical University, Beijing 100069, China

Received date: 2019-11-14

  Revised date: 2019-12-13

  Online published: 2020-04-01

Abstract

Using and adjusting the oxygen is the basic condition for higher organisms. Three British and American scientists, William G. Kaelin Jr, Sir Peter J. Ratcliffe and Gregg L. Semenza, won the Nobel Prize in physiology or medicine in 2019 for discovering the mechanisms by which cells sense and adapt to the oxygen. They have found that the hypoxia inducible factor 1 (HIF-1), an important transcription factor, is widely distributed in chronic hypoxic cells and promotes cells to adapt to the hypoxia. The HIF-1 level is regulated by the oxygen content. Under the high oxygen condition, the HIF-1 is degraded after its modification. Conversely, under the low oxygen condition, the HIF-1 is not degraded and promotes the expression of the hypoxia related genes such as the erythropoietin through the transcriptional regulation. This paper reviews the discovery and the basic molecular mechanism of the HIF-1, as well as its clinical application values.

Cite this article

ZHAO Li , LI Jie . Hypoxia adaption in life——An analysis of Nobel Prize in Physiology or Medicine in 2019[J]. Science & Technology Review, 2020 , 38(2) : 79 -85 . DOI: 10.3981/j.issn.1000-7857.2020.02.009

References

[1] Semenza G L, Rue E A, Iyer N V, et al. Assignment of the hypoxia-inducible factor 1α gene to a region of conserved synteny on mouse chromosome 12 and human chromosome 14q[J]. Genomics, 1996, 34(3):437-439.
[2] Wang G L, Semenza G L. Purification and characterization of hypoxia-inducible factor 1[J]. Journal of Biological Chemistry, 1995, 270(3):1230-1237.
[3] Benita Y, Kikuchi H, Smith A D, et al. An integrative genomics approach identifies hypoxia inducible factor-1(HIF-1)-target genes that form the core response to hypoxia[J]. Nucleic Acids Research, 2009, 37(14):4587-4602.
[4] Mole D R, Blancher C, Copley R R, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts[J]. Journal of Biological Chemistry, 2009, 284(25):16767-16775.
[5] Kim J W, Tchernyshyov I, Semenza G L, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase:A metabolic switch required for cellular adaptation to hypoxia[J]. Cell Metabolism, 2006, 3(3):177-185.
[6] Bai C, Sen P, Hofmann K, et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box[J]. Cell, 1996, 86(2):263-274.
[7] Hon W C, Wilson M I, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL[J]. Nature, 2002, 417(6892):975-978.
[8] Mcneill L A, Hewitson K S, Gleadle J M, et al. The use of dioxygen by HIF prolyl hydroxylase(PHD1)[J]. Bioorganic & Medicinal Chemistry Letters, 2002, 12(12):1547-1550.
[9] Mahon, P C. FIH-1:A novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity[J]. Genes & Development, 2001, 15(20):2675-2686.
[10] Hewitson K S, Mcneill L A, Riordan M V, et al. Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family[J]. Journal of Biological Chemistry, 2002, 277(29):26351-26355.
[11] Lando D, Peet D J, Gorman J J, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor[J]. Genes Development, 2002, 16(12):1466-1471.
[12] Muchnik E, Kaplan J. HIF prolyl hydroxylase inhibitors for anemia[J]. Expert Opinion on Investigational Drugs, 2011, 20(5):645-656.
[13] Hsieh M M, Linde N S, Wynter A, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques[J]. Blood, 2007, 110(6):2140-2147.
[14] Del Vecchio L, Locatelli F. Roxadustat in the treatment of anaemia in chronic kidney disease[J]. Expert Opinion on Investigational Drugs, 2018, 27(1):125-133.
[15] Haase V H. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism[J]. Hemodialysis International, 2017(21):110-124.
[16] Shyu K G, Wang M T, Wang B W, et al. Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat[J]. Cardiovascular Research, 2002, 54(3):576-583.
[17] Bergeron M, Gidday J M, Yu A Y, et al. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain[J]. Annals of Neurology, 2000, 48(3):285-296.
[18] Cha S T, Chen P S, Johansson G, et al. MicroRNA-519c suppresses hypoxia-inducible factor-1α expression and tumor angiogenesis[J]. Cancer Research, 2010, 70(7):2675-2685.
[19] Gravdal K, Halvorsen O J, Haukaas S A, et al. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer[J]. Cancer Research, 2009, 69(11):4708-4715.
[20] Ryan H E, Poloni M, Mcnulty W, et al. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth[J]. Cancer Research, 2000, 60(15):4010-4015.
[21] Baba Y, Nosho K, Shima K, et al. HIF1A Overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers[J]. American Journal of Pathology, 2010, 176(5):2292-2301.
[22] Griffiths E A, Pritchard S A, Mcgrath S M, et al. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.[J]. British Journal of Cancer, 2007, 96(9):1377.
[23] Speisky D, Duces A, Bièche I, et al. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients[J]. Clinical Cancer Research, 2012, 18(10):2838-2849.
[24] Ajith T A. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer[J]. Journal of Basic and Clinical Physiology and Pharmacology, 2018, 30(1):11-18.
[25] Fan L, Diao L, Chen D. Expression of HIF-1 alpha and its relationship to apoptosis and proliferation in lung cancer[J]. Chinese Journal of Cancer, 2002, 21(3):254.
[26] Ghafar M A, Anastasiadis A G, Chen M W, et al. Acute hypoxia increases the aggressive characteristics and survival properties of prostate cancer cells[J]. The Prostate, 2003, 54(1):58-67.
[27] Talks K L, Turley H, Gatter K C, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages[J]. American Journal of Pathology, 2000, 157(2):411-421.
[28] Palayoor S T, Tofilon P J, Coleman C N. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells[J]. Clinical Cancer Research, 2003, 9(8):3150-3157.
[29] Mabjeesh N J, Escuin D, Lavallee T M, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF[J]. Cancer Cell, 2003, 3(4):363-375.
[30] Palazon A, Tyrakis P A, Macias D, et al. An HIF-1α/VEGF-A axis in cytotoxic T cells regulates tumor progression[J]. Cancer Cell. 2017, 32(5):669-683.
Outlines

/